Rechallenge of denosumab in advanced giant cell tumor of the bone after atypical femur fracture: A case report and review of literature

Overview of attention for article published in Frontiers in oncology, July 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (66th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 8 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 6 X posts from 5 X users, with an upper bound of 13,769 followers.

RT @nasca_vincenzo: Adding up to the work on ONJ (https://t.co/UsHrDWEQNt), here we provide another (early) evidence that denosumab rechall…

20 Jul 2022

Reply Repost Favourite

RT @nasca_vincenzo: Adding up to the work on ONJ (https://t.co/UsHrDWEQNt), here we provide another (early) evidence that denosumab rechall…

19 Jul 2022

Reply Repost Favourite

RT @nasca_vincenzo: Adding up to the work on ONJ (https://t.co/UsHrDWEQNt), here we provide another (early) evidence that denosumab rechall…

19 Jul 2022

Reply Repost Favourite

ONJ is a major limiting side effect for denosumab use in #GCTB and a serious pt concern. Great to see denosumab rechallenge after AFF is potentially safe from risk of future path fractures. Now if only there were other Rx outside this and bisphosphonates.

19 Jul 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.